Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04111107 · ClinicalTrials.gov registry record · Phase 2
Precision Medicine for Patients With Identified Actionable Mutations
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT04111107 is a Phase 2 study that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 45 participants.
The verdict
NCT04111107, a Phase 2 study, was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
The goal of the current pragmatic trial is to evaluate the impact of a simple method of selecting a treatment approach for identified mutations on participants' progression free survival (PFS). The study also intends to collect information on barriers that investigators encounter when prescribing treatment options using the Next Generation Sequencing (NGS) reports. Additionally, patients' quality of life will be measured before, after, and during treatment. Patients will be followed until death for monitoring survival study endpoints.
Interventions
- DRUG Investigational Agent
- OTHER Supportive Care Regimens
- DIAGNOSTIC_TEST Next Gen Sequencing Report
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2020-04-22 |
| Est. Completion | 2023-02-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04111107
The ClinicalTrials.gov registry entry for NCT04111107 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Investigational Agent is the first listed.
NCT04111107 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04111107 about?
NCT04111107 is a clinical study titled "Precision Medicine for Patients With Identified Actionable Mutations". The goal of the current pragmatic trial is to evaluate the impact of a simple method of selecting a treatment approach for identified mutations on participants' progression free survival (PFS). The study also intends to collect information on barriers that investigators encounter when prescribing tr...
What is the current status of trial NCT04111107?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2020-04-22. Estimated completion is 2023-02-09.
What interventions are being tested in trial NCT04111107?
The interventions under investigation include: Investigational Agent (DRUG), Supportive Care Regimens (OTHER), Next Gen Sequencing Report (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04111107?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.